Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

Core Insights - The combination of AFM24 and atezolizumab shows promising efficacy in heavily pretreated non-small cell lung cancer (NSCLC) patients, with objective responses observed in both EGFR wild-type and mutant cohorts [1][2][3][4] Summary by Sections Efficacy Data - In the EGFR wild-type cohort, 4 objective responses were recorded, including 1 complete response (CR) and 3 partial responses (PR), with a disease control rate of 71% and a median progression-free survival (PFS) of 5.9 months [2][4] - In the EGFR mutant cohort, the combination therapy resulted in 1 CR, 3 PRs, and 6 patients with stable disease (SD), indicating potential synergistic effects [3][4] Safety Profile - The combination therapy demonstrated a manageable safety profile, with side effects consistent with known profiles of the individual agents, primarily mild to moderate infusion-related reactions and transient increases in liver enzymes [3][4] Future Developments - The study plans to enroll up to 40 patients in the EGFR wild-type cohort and 25 patients in the EGFR mutant cohort, with ongoing recruitment and further updates expected in the second half of 2024 [4] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer, utilizing its proprietary ROCK® platform to develop innate cell engagers (ICE®) [6][7]